knowledge -WSS

knowledge

author：leisure time 2025-09-03 12:08:27 - browse：166

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： GSK’s asthma push continues as drug succeeds in Phase 3 trials

focus

WSS

Leukemia patients are helped by Syndax's new type of therapy

Patients' immediate access to test results puts radiologists in a bind

FDA needs staff influx to meet gene therapy needs, Marks says

Novel spinal cord stimulator treats paralysis without surgery

Novel spinal cord stimulator treats paralysis without surgery

Teach medical students about patients with intellectual disabilities

knowledge

knowledge

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Bright Health sells Medicare Advantage business to Molina

After sickle

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Has Bernie Sanders reached the limit of his pharma bullying effort?

Medical records are filled with copy

Brain technologies pose threats that are all too real, experts warn

Bright Health sells Medicare Advantage business to Molina

The effects of a landmark ruling on DNA ownership are becoming clearer

focus

Novel spinal cord stimulator treats paralysis without surgery

Lawmakers grill UnitedHealth CEO on Change cyberattack

Empower primary care with adequate payments and technology

FDA needs staff influx to meet gene therapy needs, Marks says

CMS should re

STAT letters to the editor on burnt

focus

focus

leisure time

focus